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Abstract— Improving the quality of end-of-life care for hos-
pitalized patients is a priority for healthcare organizations.
Studies have shown that physicians tend to over-estimate prog-
noses, which in combination with treatment inertia results in
a mismatch between patients wishes and actual care at the
end of life . We describe a method to address this problem
using Deep Learning and Electronic Health Record (EHR) data,
which is currently being piloted, with Institutional Review Board
approval, at an academic medical center. The EHR data of
admitted patients are automatically evaluated by an algorithm,
which brings patients who are likely to benefit from palliative
care services to the attention of the Palliative Care team. The
algorithm is a Deep Neural Network trained on the EHR data
from previous years, to predict all-cause 3-12 month mortality of
patients as a proxy for patients that could benefit from palliative
care. Our predictions enable the Palliative Care team to take a
proactive approach in reaching out to such patients, rather than
relying on referrals from treating physicians, or conduct time
consuming chart reviews of all patients. We also present a novel
interpretation technique which we use to provide explanations of
the model’s predictions.
I. INTRODUCTION
Studies have shown that approximately 80% of Americans
would like to spend their final days at home if possible, but
only 20% do [1]. In fact, up to 60% of deaths happen in an
acute care hospital, with patients receiving aggressive care in
their final days. Access to palliative care services in the United
States has been on the rise over the past decade. In 2008,
53% of all hospitals with fifty or more beds reported having
palliative care teams, rising to 67% in 2015 [2]. However,
despite increasing access, data from the National Palliative
Care Registry estimates that less than half of the 7-8% of all
hospital admissions that need palliative care actually receive it
[3]. Though a significant reason for this gap comes from the
palliative care workforce shortage [4], and incentives for health
systems to employ them, technology can still play a crucial
role by efficiently identifying patients who may benefit most
from palliative care, but might otherwise be overlooked under
current care models.
We focus on two aspects of this problem. First, physicians
may not refer patients likely to benefit from palliative care
for multiple reasons such as overoptimism, time pressures, or
treatment inertia [5]. This may lead to patients failing to have
their wishes carried out at end of life [6] and overuse of aggres-
sive care. Second, a shortage of palliative care professionals
makes proactive identification of candidate patients via manual
chart review an expensive and time-consuming process.
The criteria for deciding which patients benefit from pal-
liative care can be hard to state explicitly. Our approach uses
deep learning to screen patients admitted to the hospital to
identify those who are most likely to have palliative care needs.
The algorithm addresses a proxy problem - to predict the
mortality of a given patient within the next 12 months - and
use that prediction for making recommendations for palliative
care referral. This frees the palliative care team from manual
chart review of every admission and helps counter the potential
biases of treating physicians by providing an objective rec-
ommendation based on the patient’s EHR. Currently existing
tools to identify such patients have limitations, and they are
discussed in the next section.
II. RELATED WORK
Accurate prognostic information is valuable to patients,
caregivers, and clinicians [7] [8]. Several studies have shown
that clinicians are generally over optimistic in their estimates
of the prognoses of terminally ill patients [9] [5] [10] [11]. It
has also been shown that no subset of clinicians are better at
late stage prognostication than than others [12] [13] . However,
clinician judgment remains the most common method of
predicting survival in practice [12]. Several solutions exist
that attempt to make patient prognosis more objective and
automated. Many of these solutions are models that produce a
score based on the patient’s clinical and biological parameters,
and can be mapped to an expected survival rate.
Prognostic tools in Palliative Care
The Palliative Performance Scale [14] was developed as
a modification of the Karnofsky Performance Status Scale
(KPS) [15] to the Palliative care setting, and is calculated
based on observable factors such as: degree of ambulation,
ability to do activities, ability to do self-care, food and fluid
intake, and state of consciousness. The Palliative Prognostic
Score (PPS) was constructed for the Palliative Care setting
as well, focusing on terminally ill cancer patients [16]. The
PPS is calculated with multiple regression analysis based on
the following variables: Clinical Prediction of Survival (CPS),
Karnofsky Performance Status (KPS), anorexia, dyspnea, total978-1-5090-1629-7/16/$31.00 c© 2017 IEEE
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white blood count (WBC) and lymphocyte percentage. The
Palliative Prognostic Index (PPI), developed around the same
time as PPS, also calculates a multiple regression analysis
based score using Performance Status, oral intake, edema,
dyspnea at rest, and delirium. These scores are difficult to
implement at scale since they involve face-to-face clinical
assessment and involve prediction of survival by the clinician.
Furthermore, these scores were designed to be used within
the palliative care setting, where the patient is already in an
advanced stage of the disease — as opposed to identifying
them earlier.
Prognostic tools in the Intensive Care Unit
There also are prognosis scoring models that are commonly
used in the Intensive Care Unit. The APACHE-II (Acute
Physiology, Age, Chronic Health Evaluation) Score predicts
hospital mortality risk for critically ill hospitalized adults in
the ICU [17]. This model has been more recently refined with
the APACHE-III Score, which uses factors such as major
medical and surgical disease categories, acute physiologic
abnormalities, age, preexisting functional limitations, major
comorbidities, and treatment location immediately prior to
ICU admission [18]. Another commonly used scoring system
in the ICU is the Simplified Acute Physiological Score, or
SAPS II [19], which is calculated based on the patient’s
physiological and underlying disease variables. While these
score are useful for the treatment team when the patient
is already in the ICU, they have limited use in terms of
identifying patients who are at risk of longer term mortality,
while they are still capable of having a meaningful discussion
of their goals and values, so that they can be set on an
alternative path of care.
Prognostic tools for Early Identification
There have been a number of studies and tools developed
that aim to identify terminally ill patients early enough for an
end-of-life plan and care to be meaningful.
CriSTAL (Criteria for Screening and Triaging to Appropri-
ate aLternative care) was developed to identify elderly patients
nearing end of life, and quantifies the risk of death in the
hospital or soon after discharge [20]. CriSTAL provides a
check list using eighteen predictors with the goal of identifying
the dying patient.
CARING is a tool that was developed to identify patients
who could benefit from palliative care [21]. The goal was to
use six simple criteria in order to identify patients who were at
risk of death within 1 year. PREDICT [22] is a screening tool
also based on six prognostic indicators, which were refined
from CARING. The model was derived from 976 patients.
The Intermountain Mortality Risk score is an all-causes
mortality prediction based on common laboratory tests [23].
The model provides score for 30-day, 1-year and 5-year
mortality risk. It was trained on a population of 71,921 and
tested on 47,458.
Cowen, M et al [24] proposed using a twenty-four factor
based prediction rule at the time of hospital admission to
identify patients with high risk of 30-day mortality, and to
organize care activities using this prediction as a context. One
of the their motivation was to have a rule from a single set of
factors, and not be disease specific. The model was derived
from 56,003 patients.
Meffert, C et al [25] proposed a scoring method based
on logistic regression on six factors to identify hospitalized
patients in need of palliative care. In this prospective study,
they asked the treating physician at the time of discharge
whether the patient had palliative care needs. The trained
model was then used to identify such patients at the time of
admission. The model was derived from 39,849 patients.
Ramachandran, K et al [26] developed a 30-day mortality
prediction tool for hospitalized cancer patients. Their model
used eight variables that were based on information from the
first 24 hours of admission, and laboratory results and vitals.
A logistic regression model was developed from these eight
variables and used as a scoring function. The model was
derived from 3,062 patients.
Amarasingham, R et al [27] built a tool to screen patients
who were admitted with heart failure, and identify those who
are at risk of 30-day readmission or death. Their regression
model uses a combination of Tabak Morality Score [28],
markers of social, behavioral, and utilization activity that
could be obtained electronically, ICD-9 CM codes specific
to depression and anxiety, billing and administrative data.
Though this study was not specifically focused on palliative
care, the methodology of using EHR system data is relevant
to our work. The model was derived from 1,372 patients.
Makar, M et al [29] used only Medicare claims data on older
population (≥ 65 years) to predict mortality in six months.
By limiting their model to use only administrative data, they
hypothesized an easier deployment scenario thereby making
automated prognostic models more prevalent. The model was
derived separately on four cohorts (one per disease type) with
20,000 patients per cohort.
Prognosis in the age of Big-Data
The proliferation of EHR systems in healthcare combined
with advances in Machine Learning techniques on high di-
mensional data provides a unique opportunity to make con-
tributions, especially in disease prognosis [30] [31]. All the
tools described above, and those we reviewed [32] [33] [34]
[35] [36], have at least one of the following limitations. They
were either derived from small data sets (limited to specific
studies or cohorts), or used too few variables (intentionally to
make the model portable, or avoid overfitting), or the model
was too simple to capture the complexities and subtleties of
human health, or was limited to certain sub-populations (based
on disease type, age etc.) We address these limitations in our
work.
III. METHODS
We approach the problem of predicting mortality from the
point of view of the palliative care team by being largely
agnostic to disease type, disease stage, severity of admission
(ICU vs non-ICU), age etc. We take a data driven approach
and build a deep learning model that considers every patient
in the EHR (with a sufficiently long history), without limiting
our analysis to any specific sub-population or cohort. In order
to make the problem of identifying patients with palliative care
needs tractable, we use the following proxy problem statement
instead:
Given a patient and a date, predict the mortality of that
patient within 12 months from that date, using EHR data of
that patient from the prior year.
We treat this as a binary classification problem and build a
supervised deep learning model to solve it. Other than building
a model that performs well on the above problem, we are
also separately interested in the model performance on a sub-
problem — the ability to predict mortality of patients who are
currently admitted. This is because it is much easier for the
palliative care staff to intervene with admitted patients.
Data Source
STRIDE (Stanford Translational Research Integrated
Database Environment) [37] is a clinical data warehouse
supporting clinical and translational research at Stanford Uni-
versity. The snapshot of STRIDE used in our work comprises
the EHR data of approximately 2 million adult and pediatric
patients cared for at either the Stanford Hospital or the Lucile
Packard Children’s hospital between 1995 and 2014.
Constructing a Dataset for Supervised Learning
Patients who have a recorded date of death are considered
positive cases; other patients are considered negative cases.
Further, we define the prediction date of a patient to be
the point in time that divides their health record timeline
into virtual future and past events. We use data from each
patient’s virtual past to make predictions about their survival
3-12 months in the future. Note that we must take care when
defining the prediction date to not violate common sense
constraints (described below) that could invalidate the labels.
We only include patients for whom it is possible to find a
prediction date that satisfies these constraints.
Positive Cases: The constraints for positive cases were
decided based on the rationale that palliative care is most
beneficial if the referral occurs 3-12 months prior to death.
Predicting mortality within 3 months is considered too late
due to the preparatory time required to start palliative care in
general. On the other hand, a lead time longer than 12 months
is problematic because making accurate predictions over such
a long time horizon is difficult, and more importantly, pal-
liative care interventions are a limited resource that are best
focused on more immediate needs. The prediction date for
positive cases must meet all the following constraints:
• The prediction date must be a recorded date of encounter.
• The prediction date must be at least 3 months prior to
date of death (otherwise death is too near).
• The prediction date can be at most 12 months prior to
date of death (otherwise death is too far).
Fig. 1. Right-censoring lengths shown as a survival plot.
• The prediction date must be at least 12 months after
the date of first encounter (otherwise the patient lacks
sufficient history on which to base a prediction).
• In-patient admissions are preferred over other admission
types for the prediction date, as long as they meet the
previous constraints (since it is easier to start the palliative
care conversation with them).
• The prediction date must be the earliest among the
possible candidate dates subject to previous constraints.
Negative Cases: For negative cases (patients without a date
of death), we require that the patient was alive for at least
12 months from the prediction date. We choose the prediction
date such that it satisfies all the following constraints:
• The prediction date must be a recorded date of encounter.
• The prediction date must be at least 12 months prior to
date of last encounter (to avoid ambiguity of death after
date of EHR snapshot).
• The prediction date must be at least 12 months after the
date of first encounter (otherwise insufficient history).
• In-patient admissions are preferred over other encounter
types for the prediction date, as long as they meet the
previous constraints (to serve as controls for the admitted
positive cases).
• The prediction date must be the latest among the possible
candidate dates subject to previous constraints.
Admitted patients: Those patients whose prediction date
corresponds to an in-patient admission are considered admit-
ted patients. Remaining patients are considered non-admitted
(note that non-admitted patients could still have other recorded
admissions in their history). Further, for admitted patients,
their prediction date it is re-adjusted by incrementing it to
be the second day of admission. The rationale for doing this
is that patient records are generally updated with the latest
data (preliminary tests, diagnostics etc.) within 24 hours of
admission, and the second day is better suited for making a
more informed prediction. Note that the admitted patients are
Alive Deceased Total
In EHR 1,880,096 131,009 201,1105
Selected 205,571 15,713 221,284
Admitted 9,648 1,131 10,779
TABLE I
BREAKDOWN OF PATIENT COUNTS.
Fig. 2. Age of patients at prediction time.
a subset of the included patients (and NOT a separate set).
All the data after the prediction date is censored in both the
positive and negative cases. The KM-plot of censor lengths is
shown in Fig 1, highlighting the separation between the two
classes at 365 days.
Data Description
The inclusion criteria selected a total of 221,284 patients.
Table I shows the breakdown of these patients based on
inclusion and admission.
We observe that, unsurprisingly, the distribution of age at
prediction time is not equal between the classes, and that the
positive class (of deceased patients) is skewed towards older
age (Fig 2).
The included patients are randomly split in approximate
ratio 8:1:1 into training, validation and test sets, as shown
in Table II.
The prevalence of death among the included patients is
approximately 7%. Approximately 5% were admitted patients
(i.e., prediction date was the second day of an admission).
Training Validation Testing
Alive 164,424 20,619 20,528 205,571
Deceased 12,587 1,520 1,606 15,713
177,011 22,139 22,134 221,284
TABLE II
DATA SPLIT FOR MODELING.
Start date End date Duration
observation window PD - 365 PD 365
observation slice 1 PD - 30 PD 30
observation slice 2 PD - 90 PD - 30 60
observation slice 3 PD - 180 PD - 90 90
observation slice 4 PD - 365 PD - 180 185
TABLE III
OBSERVATION WINDOW AND SLICES
Among the admitted patients, the prevalence of death is about
11%.
Feature Extraction
For each patient, we consider the 12 months leading up
to their prediction date as their observation window. Within
the observation window of each patient, we use ICD9 (In-
ternational Classification of Diseases 9th rev) diagnostic and
billing codes, CPT (Current Procedural Terminology) proce-
dure codes, RxNorm prescription codes, and encounters found
in that period to create features.
We create features as follows. In order to capture the lon-
gitudinal nature of the data, we split the observation window
of each patient into four observation slices, specified relative
to the prediction date (PD) as shown in Table III
Thus, observation slice 1 is the most recent, and 4 is the
oldest. The slice widths are intentionally uneven in order to
give more emphasis to recent data. Within each observation
slice, we count the the number of occurrences of each code
in each code category (prescription, billing, etc.) per patient.
The count of every such code within the slice is considered a
separate feature.
We also include the patient demographics (age, gender, race
and ethnicity), and the following per-patient summary statistics
in the observation window for each code category:
• Count of unique codes in the category.
• Count of total number of codes in the category.
• Maximum number of codes assigned in any day.
• Minimum number of codes (non-zero) assigned in any
day.
• Range of number of codes assigned in a day.
• Mean of number of codes assigned in a day.
• Variance in number of codes assigned in a day.
All these features (i.e, code counts in each of the four
observation slices, per category summary statistics over the
observation window, and demographics) were concatenated
to form the candidate feature set. From this set, we pruned
away those features which occur in 100 or fewer patients.
This resulted in the final set of 13,654 features. Of the 13,654
features, each patient on average has 74 non-zero values (with
a standard deviation of 62), and up to a maximum of 892
values. The overall feature matrix is approximately 99.5%
sparse.
Fig. 3. Reliability curve (calibration plot) of the model output probabilities
on the test set data.
Algorithm and Training
Our model is a Deep Neural Network (DNN) [38] compris-
ing an input layer (of 13,654 dimensions), 18 hidden layers
(each 512 dimensions) and a scalar output layer. We employ
the logistic loss function at the output layer and use the Scaled
Exponential Linear Unit (SeLU) activation function [39] at
each layer. The model is optimized using the Adam optimizer
[40], with a mini-batch size of 128 examples. Intermediate
model snapshots were taken every 250 mini-batch iterations,
and the snapshot that performed best on the validation test was
selected as the final model. Explicit regularization was not
found necessary. The network configuration was reached by
extensive hyperparameter search over various network depths
(ranging from 2 to 32) and activation functions (tanh, ReLU
and SeLU ).
The software was implemented using the Python program-
ming language (version 2.7), PyTorch framework [41], and
the scikit-learn library (version 0.17.1) [42]. The training was
performed on an NVIDIA TitanX (12GB RAM) with CUDA
version 8.0.
Evaluation
Since the data is imbalanced (with 7% prevalence), accuracy
can be a poor evaluation metric [43]. The ROC curve can
also be sometimes misleading on imbalanced problems [44]
[45]. Therefore, we use the Average Precision (AP) score, also
known as Area Under Precision-Recall Curve (AUPRC) for
model selection [46].
IV. RESULTS
In this section we report technical evaluation results ob-
tained on the test set using the model selected based on the
best AP score on the validation set.
We observe that the model is reasonably calibrated (Fig 3)
with a Brier score of 0.042. In the high threshold regime,
which is of interest to us, the model is a little conservative
Fig. 4. Interpolated Precision-Recall curve. The horizontal dotted line
represents precision level of 0.9. The vertical dotted lines indicate the recall
at which the curves achieve 0.9 precision.
Fig. 5. Receiver Operating Characteristic (ROC) of the model performance
on the test set.
(under-confident) in its probability estimates, which should not
hurt.
The interpolated Precision-Recall curve is shown in Fig 4.
The model achieves an AP score of 0.69 (0.65 on admitted
patients). Early recall is desirable, and therefore Recall at
precision 0.9 is a metric of interest. The model achieves recall
of 0.34 at 0.9 precision (0.32 on admitted patients). The
Receiver Operating Characteristic curve is shown in Fig 5.
The model achieves an AUROC of 0.93 (0.87 for admitted
patients). Both the ROC and Precision-Recall plots suggest
that the model demonstrates strong early recall behavior.
Qualitative Analysis
It is worth recalling that predicting mortality was a proxy
problem for identifying patients who could benefit from pal-
liative care. In order to evaluate our performance on the
Patient MRN XXXXXXX
Probability score 0.946
Factors Code Value Influence Description
Top Diagnostic factors V10.51 4 0.0051 Personal history of malignant neoplasm of bladder
V10.46 5 0.0019 Personal history of malignant neoplasm of prostate
518.5 1 0.0012 Pulmonary insufficiency following trauma and surgery
518.82 1 0.0008 Other pulmonary insufficiency
88.75 1 0.0006 Diagnostic ultrasound of urinary system
Top Procedural factors 88331 1 0.0017 Pathology consultation during surgery with FS
75984 1 0.0014 Transcatheter Diagnostic Radiology Procedure
72158 1 0.0013 MRI and CT Scans of the Spine
Code Type Count 76 0.0011 Summary statistic (count of all ICD/CPT codes)
76005 1 0.0007 Fluroscopic guidance and localization of needle or catheter tip for spine
Top Medication factors
Top Encounter factors Hx Scan 21 0.0012 Number of scan encounters of all types
Inpatient 60 0.0004 Number of days patient was admitted
Var Codes per Day 8 0.0002 Summary statistic (variance in number of codes assigned per day)
Code Day Count 88 0.0001 Number of days any encounter code was assigned
Top Demographic factors Age 81 0.0010 Age of patient in years at prediction time
TABLE IV
PREDICTION EXPLANATION GENERATED ON A RANDOM POSITIVE PATIENT WITH HIGH PROBABILITY SCORE. ONLY FACTORS THAT CONTRIBUTED TO A
DROP IN PROBABILITY SCORE ARE REPORTED.
Patient MRN YYYYYYY
Probability score 0.909
Factors Code Value Influence Description
Top Diagnostic factors 197.7 16 0.1299 Malignant neoplasm of liver, secondary
154.1 3 0.1254 Malignant neoplasm of rectum
287.5 1 0.0194 Thrombocytopenia, unspecified
780.6 1 0.0171 Fever and other physiologic disturbances of temperature regulation
733.90 1 0.0113 Other and unspecified disorders of bone and cartilage
Top Procedural factors 73560 1 0.0502 Diagnostic Radiology (Diagnostic Imaging) Procedures of the Lower Extremities
Code Type Count 20 0.0491 Summary statistic (Number of unique ICD-9/CPT codes)
74160 1 0.0381 Diagnostic Radiology (Diagnostic Imaging) Procedures of the Abdomen
Max Codes per Day 6 0.0234 Summary statistic (Maximum number of codes in any day)
Range Codes per Day 6 0.0233 Summary statistic (Range of codes across days)
Top Medication factors 283838 1 0.0619 Darbepoetin Alfa
28889 1 0.0247 Loratadine
Range Codes per Day 5 0.0023 Summary statistic (Ranges of codes across days)
Max Codes per Day 5 0.0023 Summary statistic (Maximum number of codes in any day)
Code Type Count 6 0.0015 Summary statistic (Number of unique medication codes)
Top Encounter factors Hx Scan 19 0.2239 Number of scan encounters of all types
Code Day Count 97 0.0284 Number of days any encounter code was assigned
Outpatient 22 0.0228 Number of Outpatient encounters
Var Codes per Day 1 0.0074 Summary statistic (variance in number of codes assigned per day)
Top Demographic factors
TABLE V
PREDICTION EXPLANATION GENERATED ON A RANDOM FALSE POSITIVE PATIENT WITH HIGH PROBABILITY SCORE. ONLY FACTORS THAT CONTRIBUTED
TO A DROP IN PROBABILITY SCORE ARE REPORTED.
original problem, we inspected false positives with high output
probability. Although such patients did not die within 12
months from their prediction dates, we noted that they were
often diagnosed with terminal illness and/or are high utilizers
of healthcare services. This can be seen in the positive and
false positive examples shown in Section V.
Upon conducting a chart review of 50 randomly chosen
patients in the top 0.9 precision bracket of the test set, the
palliative care team found all were appropriate for a referral
on their prediction date, even if they survived more than a
year. This suggests that mortality prediction was a reasonable
(and tractable) choice of a proxy problem to solve.
V. EXPLAINING PREDICTIONS
Supervised machine learning techniques, and in particular
Deep Learning techniques, have recently demonstrated tremen-
dous success in predictive ability. However, better performance
often requires larger, more complex models and thus sacrifice
interpretability. It is worth drawing a distinction between
interpreting a model, versus interpreting its decision [47] [48].
While interpreting complex models (e.g very deep neural
networks) may sometimes be infeasible, it is often the case that
users only want an explanation for the prediction made by the
model for a given example. It is important to establish the trust
of the practitioner in the model’s decisions for them to feel
comfortable taking actions based on it. Providing explanations
along with decisions help establish that trust.
We make the following observations to motivate our expla-
nation technique.
• We can view the EHR data as a strictly growing log
of events, and that new data is only added (nothing
is modified or removed in general). This results in all
our features being positive valued (as counts, means and
variance of counts, etc).
• We are most interested in explaining why a model assigns
high probability to a patient. We are less interested in
getting an explanation for why a healthy person was given
a low probability (the reasons are also much less clear: the
patient did not have brain cancer, did not have pneumonia,
and so on).
• Directly perturbing feature vectors (e.g sensitivity anal-
ysis or for techniques described in [47]) does not work
well in our case . For example, perturbing the feature
representing the ICD count for brain cancer from zero
to non zero can increase the probability of death signifi-
cantly, implying that it is an important factor in general.
However, that is not a very useful observation for a
specific patient who does not have brain cancer.
These observations motivate the following technique. For
each ICD-9, CPT, RXNORM and Encounter code, we ablate
all occurrences of that code from the patient’s EHR, create a
new feature vector, and measure the drop in probability com-
pared to the original probability. This corresponds to asking:
all else being equal, how would the probability change if this
patient was not diagnosed with XYZ, prescribed drug ABC,
etc? This drop in probability is considered the influence the
code has on the model’s decision for that patient. Demographic
features are handled as follows. We zero out the age and swap
the gender to the opposite sex, and measure the respective
drops in probability. Finally we sort the codes in descending
order by influence, and pick the top 5 in each code category.
A random example of such a positive and false positive case
are shown in Table IV and V.
VI. CONCLUSION
We demonstrate that routinely collected EHR data can be
used to create a system that prioritizes patients for follow
up for palliative care . In our preliminary analysis we find
that it is possible to create a model for all-cause mortality
prediction and use that outcome as a proxy for the need of a
palliative care consultation. The resulting model is currently
being piloted for daily, proactive outreach to newly admitted
patients. We will collect objective outcome data (such as
rates of palliative care consults, and rates of goals of care
documentation) resulting from the use of our model . We also
demonstrate a novel method of generating explanations from
complex deep learning models that helps build confidence of
practitioners to act on the recommendations of the system.
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